Premium
Proteomics in pancreatic cancer research
Author(s) -
Cecconi Daniela,
Palmieri Marta,
Donadelli Massimo
Publication year - 2011
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201000401
Subject(s) - proteomics , pancreatic cancer , metastasis , biology , carcinogenesis , quantitative proteomics , cancer , cancer research , cytoskeleton , bioinformatics , mechanism (biology) , computational biology , cell , biochemistry , genetics , gene , philosophy , epistemology
Abstract In this review, we give an overview of the actual role of proteomic technologies in the study of pancreatic cancers (PCs). We describe PC proteomics on the basis of sample origins, i.e. tissues, body fluids, and PC cell lines. As regards PC tissues, we report the identification of a number of candidate biomarkers of precursor lesions that may allow early diagnosis of this neoplasia. Moreover, we describe cytoskeletal and hypoxia‐regulated proteins that confirm the involvement of cytoskeleton modifications and metabolism adaptations in carcinogenesis. We also discuss the most important biomarkers identified by proteomic analysis involved in local invasion and distant metastasis, and in the cross‐talk between pancreatic tumor and the surrounding stroma. Furthermore, we report novel candidate biomarkers identified in serum, plasma, and pancreatic juice of cancer patients compared with cancer‐free controls. Proteomic alterations in PC cell line models as compared to normal controls and studies on cell lines treated with drugs or new agents to understand their mechanism of pharmacological action or the onset of drug resistance are also presented. Finally, we discuss the recent improvements obtained in classical 2‐DE and high‐throughput proteomic strategies able to allow the overcoming of relevant proteomic drawbacks.